Form 4: IGMS Director Reports Share Conversion Post-Merger

A director of IGM Biosciences, Inc. reported the conversion of all common stock holdings into cash and contingent value rights following the company's merger with Concentra Biosciences, LLC.

Summary

• Elizabeth H.Z. Thompson, a Director of IGM Biosciences, Inc. (IGMS), reported a change in beneficial ownership.
• On August 14, 2025, IGM Biosciences, Inc. completed a merger with Concentra Merger Sub V, Inc., a wholly-owned subsidiary of Concentra Biosciences, LLC.
• As a result of the merger, IGM Biosciences, Inc. became a wholly-owned subsidiary of Concentra Biosciences, LLC.
• Each outstanding share of IGM Biosciences' Common Stock was cancelled.
• Shareholders received $1.247 in cash per share.
• Shareholders also received one contractual contingent value right (CVR) per share, subject to a Contingent Value Rights Agreement.
• Elizabeth H.Z. Thompson disposed of 7,196 shares of Common Stock in this transaction.
• Following the merger, Elizabeth H.Z. Thompson beneficially owns 0 shares of IGM Biosciences, Inc. Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive for shareholders who received cash and CVRs, but neutral for the company as it ceases to be an independent entity. The CVR introduces uncertainty, preventing a higher score.

Positives

• Shareholders received a cash payment of $1.247 per share.
• Shareholders received Contingent Value Rights (CVRs), offering potential future value based on specific conditions.

Negatives

• IGM Biosciences, Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary.
• Existing common stock was cancelled, removing direct equity ownership in the company.
• The value of the CVRs is contingent and not guaranteed.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and depends on future events or performance metrics as defined in the CVR Agreement.
• Shareholders no longer have direct equity exposure to IGM Biosciences, Inc.'s future performance as a standalone public company.

Future Outlook

IGM Biosciences, Inc. has become a wholly-owned subsidiary of Concentra Biosciences, LLC, implying its future operations will be integrated under the parent company. The Contingent Value Rights (CVRs) represent a future potential payout based on specific, undisclosed conditions.

Industry Context

This transaction represents a consolidation event within the biotechnology or pharmaceutical sector, where smaller companies like IGM Biosciences are acquired by larger entities like Concentra Biosciences. Such mergers are common for companies seeking to integrate specific technologies, pipelines, or market positions, often driven by strategic alignment or financial considerations. The use of CVRs is a common mechanism in biotech mergers to bridge valuation gaps or share future risks/rewards related to clinical milestones or regulatory approvals.

Comparison to Industry Standards

• The specific terms of the merger, including the $1.247 cash component and the CVR, would typically be evaluated against recent M&A transactions in the biotechnology sector involving companies at a similar stage of development or with comparable asset portfolios.
• Without specific details on the CVR terms (e.g., milestones, caps), a direct comparison to other CVR structures (e.g., those used in the acquisition of Acceleron Pharma by Merck, or the acquisition of MyoKardia by Bristol Myers Squibb) is limited.
• The cash component of $1.247 per share would be benchmarked against the company's pre-announcement trading price and analyst price targets to assess the premium offered to shareholders.

Stakeholder Impact

• Shareholders: Received cash and CVRs in exchange for their shares, losing direct equity in IGM Biosciences.
• Employees: Future employment status and benefits will be subject to the policies of the new parent company, Concentra Biosciences, LLC.
• Customers/Suppliers: Operations of IGM Biosciences will continue under new ownership, potentially leading to changes in business relationships over time.

Next Steps

• Future performance of the Contingent Value Rights (CVRs) will depend on the terms and conditions outlined in the CVR Agreement.
• Integration of IGM Biosciences, Inc. into Concentra Biosciences, LLC.

Key Dates

Keywords

IGM Biosciences, IGMS, Merger, Acquisition, SEC Form 4, Beneficial Ownership, Contingent Value Rights, CVR, Concentra Biosciences, Corporate Action